Anti-Rheumatic Rx

Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.com First In Class, TYK2 Inhibitor FDA Approved for Psoriasis 2022 New ACR Guidance…

Bags are packed, ready to go, but wait there’s more abstracts to show. The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference. Non-steroidal anti-inflammatory drugs (…

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic…

By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around (lots of sneaker mileage)!  And congrats to…

A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon.  The latter covering topics like sarcoidosis,…

EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones…

It’s good to be back into full, big meeting mode. Multinational throngs of half-masked people, long security lines, limited seating, obstructed views, an abundance of little coffee options, no food…

Intervention in individuals predisposed to develop rheumatoid arthritis (RA), with a holy grail of prevention of RA, has long been a hot topic. It is well known that seropositivity for rheumatoid…